Neotigason

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 10 USDMF, 6 CEP/COS, 3 EU WC, 7 NDC API, 5 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

84 FDF Dossiers, 23 FDA Orange Book, 38 Europe, 6 Canada, 4 Australia, 4 South Africa, 9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 17.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 SPI Pharma, 7 DKSH, 3 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 18 BASF, 2 DFE Pharma, 1 Esteem Industries, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 1 Kerry, 1 Keval Exports, 3 Lonza Capsugel, 3 Microlex e.U, 2 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 2 Pluviaendo, 1 Prachin Chemical, 1 Qualicaps, 14 Roquette, 1 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 1 Silverline Chemicals, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders, 21 Thickeners and Stabilizers, 16 Granulation, 15 Solubilizers, 15 Direct Compression, 11 Coating Systems & Additives, 8 Co-Processed Excipients, 8 Film Formers & Plasticizers, 8 Empty Capsules, 7 Taste Masking, 7 Topical, 7 Controlled & Modified Release, 6 Parenteral, 5 Disintegrants & Superdisintegrants, 4 Lubricants & Glidants, 4 Chewable & Orodispersible Aids, 3 Emulsifying Agents, 3 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Rheology Modifiers

DIGITAL CONTENT

3 News #PharmaBuzz

3 News #PharmaBuzz

GLOBAL SALES INFORMATION

5 US Medicaid Prescriptions, 23 Regulatory FDF Prices

MARKET PLACE

9 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Innovaderm

Canada

Peptide Process CMC

Not Confirmed

02

The University of Pittsburgh School of Medicine

U.S.A

Peptide Process CMC

Not Confirmed

03

Amylynne Frankel

Country

Peptide Process CMC

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for Neotigason

Neotigason

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers

10 USDMF

6 CEP/COS

3 EU WC

7 NDC API

5 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

84 FDF Dossiers

23 FDA Orange Book

38 Europe

6 Canada

4 Australia

4 South Africa

9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 17.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 SPI Pharma

7 DKSH

3 Boai NKY Pharmaceuticals Ltd

2 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

2 Kirsch Pharma

4 ACG Worldwide

1 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

18 BASF

2 DFE Pharma

1 Esteem Industries

1 Finar

6 Gangwal Chemicals

1 Ideal Cures

1 Kerry

1 Keval Exports

3 Lonza Capsugel

3 Microlex e.U

2 Nanjing Bold Chemical

1 Nitika Pharmaceutical Specialities

1 Novo Excipients

2 Pharmatrans-Sanaq

2 Pluviaendo

1 Prachin Chemical

1 Qualicaps

14 Roquette

1 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

1 Silverline Chemicals

1 Ulanqab Kema New Material

1 Valens Pharmachem

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders

21 Thickeners and Stabilizers

16 Granulation

15 Solubilizers

15 Direct Compression

11 Coating Systems & Additives

8 Co-Processed Excipients

8 Film Formers & Plasticizers

8 Empty Capsules

7 Taste Masking

7 Topical

7 Controlled & Modified Release

CAPSULE;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 17.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 22.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons